Preferred Label : Dasatinib Anhydrous;

NCIt definition : An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.;

UNII : X78UG0A0RN;

InChIKey : ZBNZXTGUTAYRHI-UHFFFAOYSA-N;

CAS number : 302962-49-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 302962-49-8 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Chemical formula : C22H26ClN7O2S;

ChEBI ID : CHEBI:49375;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accordpharma
2022
false
false
false
Netherlands
French
English
Dasatinib
Dasatinib
Dasatinib Anhydrous
dasatinib
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drugs, generic

---
Nous contacter.
14/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.